BMW

View Complaint Frequently Asked Questions info@portnoylaw.com It is alleged in this lawsuit that defendants throughout the Class Period made misleading and/or false statements and/or failed to disclose that: (1) regardless of when the sales actually occurred, BMW kept a “bank” of retail vehicle sales that it used to meet internal monthly sales targets; (2) sales...

0October 28, 2020October 28, 2020

Turquoise Hill

View Complaint Frequently Asked Questions info@portnoylaw.com Turquoise announced in a press release on February 26, 2019 that, while “the [Oyu Tolgoi] project cost was expected to remain within the $5.3 billion budget,” a review had determined that “there was an increasingly likely risk of a further delay to sustainable first production beyond Q3‘21.” Turquoise Hill...

0October 22, 2020October 22, 2020

Vivint

View Complaint Frequently Asked Questions info@portnoylaw.com The investigation focuses on whether Vivint issued misleading and/or false statements and/or failed to disclose information pertinent to investors. Vivint Smart Home, Inc. Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com. Are you a current or...

0October 16, 2020October 16, 2020

Credit Acceptance

View Complaint Frequently Asked Questions info@portnoylaw.com On August 28, 2020, a lawsuit was filed against Credit Acceptance by the Massachusetts Attorney General which alleges that the Company has, for years, been making deceptive and unfair automobile loans to thousands of Massachusetts consumers. The lawsuit also alleges that Credit Acceptance provided its investors with false and/or...

0October 16, 2020October 16, 2020

Homology

View Complaint Frequently Asked Questions info@portnoylaw.com In June 2019, Homology launched a dose-escalation Phase 1/2 clinical trial for HMI-102, its lead product candidate for the treatment of phenylketonuria. The Company "reported encouraging safety and efficacy data from the dose-escalation portion of the trial" and claimed that the data showed HMI-102 "produced a sustained reduction in...

0October 13, 2020October 14, 2020

LOOP

View Complaint Frequently Asked Questions info@portnoylaw.com The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Loop is the subject of a report issued by Hindenburg Research on October 13, 2020. The report, titled "Loop Industries: Former Employees and Plastics Experts Blow The Whistle On...

0October 13, 2020October 14, 2020

Pintec

View Complaint Frequently Asked Questions info@portnoylaw.com According to the lawsuit, throughout the Class Period the defendants made misleading and/or false statements and/or failed to disclose that: (1) GOL had material weaknesses in its internal controls; (2) there was substantial doubt as to the GOL’s ability to continue to operate as a going concern, as a...

0October 8, 2020October 14, 2020

Precigen

View Complaint Frequently Asked Questions info@portnoylaw.com On September 25, 2020, it was announced by the U.S. Securities and Exchange Commission (“SEC”) that a $2.6 million civil penalty against Intrexon related to its statements about the “purported success converting relatively inexpensive natural gas into more expensive industrial chemicals using a proprietary methane bioconversion (‘MBC’) program.” In...

0October 8, 2020October 14, 2020

Nextcure

View Complaint Frequently Asked Questions info@portnoylaw.com NextCure disclosed on January 13, 2020 that Eli Lilly and Company had ended its collaboration agreement for the research and development of NC318, Nextcure’s leading product candidate, a first-in-class immunomedicine targeting the Siglec-15 immunomodulatory receptor, particularly for patients with advanced or metastatic solid tumors. On January 13, 2020, Nextcure's...

0October 8, 2020October 14, 2020

Aurora

View Complaint Frequently Asked Questions info@portnoylaw.com A press release was issued by Aurora on September 8, 2020, “announc[ing] an update on its business operations along with certain unaudited preliminary fiscal fourth-quarter 2020 results.” Aurora announced that the Company expected to record up to $1.8 billion in goodwill impairment charges in the fourth quarter of 2020....

0October 8, 2020October 14, 2020